X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will develop Carisma's lead candidate CT-0508, a CAR-M cell therapy and will also accelerate the growth of company's platform and pipeline within and outside of oncology.
Lead Product(s): CT-0508,Pembrolizumab
Therapeutic Area: Oncology Product Name: CT-0508
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Carisma Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 21, 2023
Details:
Vicineum (oportuzumab monatox) is an investigational locally administered recombinant fusion protein that targets epithelial cell adhesion molecule antigens on the surface of tumor cells to deliver Pseudomonas Exotoxin A.
Lead Product(s): Oportuzumab Monatox
Therapeutic Area: Oncology Product Name: Vicineum
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Carisma Therapeutics
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Merger December 29, 2022
Details:
The first clinical application of this technology is CT-0508, a CAR-M cell therapy currently being evaluated by Carisma in a Phase 1 multi-center clinical trial with a lead target indication of advanced HER2+ solid tumors.
Lead Product(s): CT-0508
Therapeutic Area: Oncology Product Name: CT-0508
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Carisma Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 21, 2022
Details:
VB4-845 (vicineum), a locally administered fusion protein for treatment of NMIBC, is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule antigens on surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A. V.
Lead Product(s): Vicineum
Therapeutic Area: Oncology Product Name: VB4-845
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A.
Lead Product(s): Oportuzumab Monatox-qqrs
Therapeutic Area: Oncology Product Name: Vicineum
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A.
Lead Product(s): Oportuzumab Monatox
Therapeutic Area: Oncology Product Name: Vicineum
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 13, 2021
Details:
Vicineum is comprised of a recombinant fusion protein that targets EpCAM antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A. It is currently under Priority Review with the FDA with a target PDUFA date of August 18, 2021.
Lead Product(s): Oportuzumab Monatox-qqrs
Therapeutic Area: Oncology Product Name: Vicineum
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2021
Details:
Vicineum is constructed with a stable, genetically engineered peptide tether to ensure the payload remains attached to the antibody binding fragment until it is internalized by the cancer cell.
Lead Product(s): Oportuzumab Monatox-qqrs
Therapeutic Area: Oncology Product Name: Vicineum
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2021
Details:
Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC).
Lead Product(s): Oportuzumab Monatox-qqrs
Therapeutic Area: Oncology Product Name: Vicineum
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Viventia Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC). The BLA is supported by strong Phase 3 VISTA trial data and positive analytical comparability data.
Lead Product(s): Vicineum
Therapeutic Area: Oncology Product Name: VB4-845
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
